^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecvayli (teclistamab-cqyv)

    i
    Other names: JNJ-64007957, JNJ 64007957, JNJ64007957, JNJ 7957, Ab-957, Ab 957, Ab957, JNJ7957
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    1d
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    2d
    iFIT: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (clinicaltrials.gov)
    P3, N=1226, Not yet recruiting, University of Leeds
    New P3 trial
    |
    IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    8d
    Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1. (PubMed, Haematologica)
    Finally, a reduction in BCMA receptor density was observed on bone marrow tumor plasma cells at relapse. Our data highlight the importance of understanding mechanisms of response, resistance, and relapse to teclistamab to optimize T-cell and bispecific antibody activity, advance dosing and sequencing strategies, and inform further evaluation of teclistamab combinations with other anti-myeloma agents and use in earlier lines of treatment to improve patient outcomes.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    Tecvayli (teclistamab-cqyv)
    8d
    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv)
    13d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    13d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    13d
    TEAM MDA5: Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Tecvayli (teclistamab-cqyv)
    14d
    A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=40, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    |
    Tecvayli (teclistamab-cqyv)
    14d
    MMRC Horizon One: RRMM (MMRC-099) (clinicaltrials.gov)
    P2, N=300, Active, not recruiting, Multiple Myeloma Research Consortium | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tecvayli (teclistamab-cqyv)
    15d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    23d
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    lenalidomide • carfilzomib • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • plerixafor
    1m
    MASTER-2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (clinicaltrials.gov)
    P2, N=300, Recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • melphalan • Tecvayli (teclistamab-cqyv)